The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Open accessAbstract
We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves DC 50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, respectively. ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression. ARD-69 potently inhibits cell growth in these AR-positive prostate cancer cell lines and is >100 times more potent than AR antagonists. A single dose of ARD-69 effectively reduces the level of AR protein in xenograft tumor tissue in mice. Further optimization of ARD-69 may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
The Diagnosis and Treatment of Prostate Cancer: A Review
Litwin, M. S., & Tan, H.-J. (2017) · JAMA · doi:10.1001/jama.2017.7248 · Cited by 1,435
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1296 · Cited by 877
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Stols, L., Gu, M., Dieckman, L., Raffen, R., Collart, F. R., & Donnelly, M. I. (2002) · Protein Expression and Purification · doi:10.1006/prep.2001.1603 · Cited by 526
Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.-Y., Zhao, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 358
Self-citationSalami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281
Self-citationPereira de Jésus‐Tran, K., Côté, P., Cantin, L., Blanchet, J., Labrie, F., & Breton, R. (2006) · Protein Science · doi:10.1110/ps.051905906 · Cited by 278
Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., & Wongvipat, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901488g · Cited by 266
Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L., Epemolu, O., Shimamura, S., Bantscheff, M., Grandi, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms13312 · Cited by 239
Sun, H., Nikolovska-Coleska, Z., Lu, J., Meagher, J. L., Yang, C.-Y., Qiu, S., Tomita, Y., Ueda, Y., Jiang, S., Krajewski, K., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja074725f · Cited by 209
Self-citationTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
Small‐Molecule‐Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
Gustafson, J. L., Neklesa, T. K., Cox, C. S., Roth, A. G., Buckley, D. L., Tae, H. S., Sundberg, T. B., Stagg, D. B., Hines, J., McDonnell, D. P., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201503720 · Cited by 206
Lu, J., Bai, L., Sun, H., Nikolovska-Coleska, Z., McEachern, D., Qiu, S., Miller, R. S., Yi, H., Shangary, S., Sun, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2655 · Cited by 201
Self-citationTargeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
Self-citationChemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Powell, C. E., Gao, Y., Tan, L., Donovan, K. A., Nowak, R. P., Loehr, A., Bahcall, M., Fischer, E. S., Jänne, P. A., George, R. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01655 · Cited by 198
Ishoey, M., Chorn, S., Singh, N., Jaeger, M. G., Brand, M., Paulk, J., Bauer, S., Erb, M. A., Parapatics, K., Müller, A. C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00969 · Cited by 177
Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 165
Shibata, N., Nagai, K., Morita, Y., Ujikawa, O., Ohoka, N., Hattori, T., Koyama, R., Sano, O., Imaeda, Y., Nara, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00168 · Cited by 148
Nuclear Androgen Receptor Regulates Testes Organization and Oocyte Maturation in Zebrafish
Crowder, C. M., Lassiter, C. S., & Gorelick, D. A. (2017) · Endocrinology · doi:10.1210/en.2017-00617 · Cited by 106
Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8
Hatcher, J. M., Wang, E. S., Johannessen, L. H., Kwiatkowski, N. P., Sim, T., & Gray, N. S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00011 · Cited by 94
Zhu, S. L., Zhao, D., Lin, Y., Jiang, W., Kim, J., Gu, B., Liu, Q., Wang, R., Xia, B., Zhao, J. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02863-3 · Cited by 88
EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins
Gollavilli, P. N., Pawar, A., Wilder-Romans, K., Natesan, R., Engelke, C. G., Dommeti, V. L., Krishnamurthy, P. M., Nallasivam, A., Apel, I. J., Xu, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0484 · Cited by 80
Self-citationPal, S. K., Patel, J., He, M., Foulk, B., Kraft, K., Smirnov, D. A., Twardowski, P. W., Kortylewski, M., Bhargava, V., & Jones, J. O. (2017) · Cancer · doi:10.1002/cncr.31161 · Cited by 79
Wang, C., Peng, G., Huang, H., Liu, F., Kong, D.-P., Dong, K., Dai, L., Zhou, Z., Wang, K., Yang, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2446 · Cited by 78
Self-citationMunuganti, R. S. N., Hassona, M. D. H., Leblanc, E., Frewin, K., Singh, K., Ma, D., Ban, F., Hsing, M., Adomat, H. H., Lallous, N., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.012 · Cited by 76
Guerrini, A., Tesei, A., Ferroni, C., Paganelli, G., Zamagni, A., Carloni, S., Donato, M. D., Castoria, G., Leonetti, C., Porru, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5005122 · Cited by 75
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Guo, C., Linton, A., Kephart, S. E., Ornelas, M. A., Pairish, M., González, J., Greasley, S. E., Nagata, A., Burke, B. J., Edwards, M. P., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201059s · Cited by 71
Seamless Insert-Plasmid Assembly at High Efficiency and Low Cost
Benoit, R., Ostermeier, C., Geiser, M., Li, J. S. Z., Widmer, H., & Auer, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153158 · Cited by 46
Liu, V., Yau, W., Tam, C. W., Yao, K., & Shiu, S. Y. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061130 · Cited by 39
Lottrup, G., Jørgensen, A., Nielsen, J. E., Jørgensen, N., Dunø, M., Vinggaard, A. M., Skakkebæk, N. E., & Meyts, E. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1278 · Cited by 31
Yamamoto, S., Tomita, N., Suzuki, Y., Suzaki, T., Kaku, T., Hara, T., Yamaoka, M., Kanzaki, N., Hasuoka, A., Baba, A., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.005 · Cited by 30
Oksala, R., Moilanen, A., Riikonen, R., Rummakko, P., Karjalainen, A., Passiniemi, M., Wohlfahrt, G., Taavitsainen, P., Mälmström, C., Ramela, M., et al. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.02.004 · Cited by 23
Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators
Sundén, H., Holland, M. C., Poutiainen, P., Jääskeläinen, T. J., Pulkkinen, J. T., Palvimo, J. J., & Olsson, R. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501995n · Cited by 20
Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer
Narayanan, R., Ponnusamy, S., & Miller, D. D. (2017) · Oncoscience · doi:10.18632/oncoscience.389 · Cited by 17
Cited by
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 576
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Metadata
- Authors
- Han, X., Wang, C., Qin, C., Xiang, W., Fernandez-Salas, E., Yang, C.-Y., Wang, M., Zhao, L., Xu, T., Chinnaswamy, K., Delproposto, J., Stuckey, J., & Wang, S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-01-10
- Volume
- 62
- Issue
- 2
- Pages
- 941-964
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2909034820
- Cited by
- 381
- References
- 44
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.